| 000 | 01020 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517132117.0 | ||
| 264 | 0 | _c20180628 | |
| 008 | 201806s 0 0 chi d | ||
| 022 | _a1009-2137 | ||
| 024 | 7 |
_a10.7534/j.issn.1009-2137.2016.06.050 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAn, Ran | |
| 245 | 0 | 0 |
_a[Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review]. _h[electronic resource] |
| 260 |
_bZhongguo shi yan xue ye xue za zhi _cDec 2016 |
||
| 300 |
_a1888-1891 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdaptor Proteins, Signal Transducing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMultiple Myeloma |
| 650 | 0 | 4 | _aPeptide Hydrolases |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aThalidomide |
| 650 | 0 | 4 | _aUbiquitin-Protein Ligases |
| 700 | 1 | _aHou, Jian | |
| 773 | 0 |
_tZhongguo shi yan xue ye xue za zhi _gvol. 24 _gno. 6 _gp. 1888-1891 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7534/j.issn.1009-2137.2016.06.050 _zAvailable from publisher's website |
| 999 |
_c26732572 _d26732572 |
||